{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:34:56Z","timestamp":1777581296948,"version":"3.51.4"},"reference-count":28,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,9]]},"abstract":"<jats:p>Myositis and rhabdomyolysis are the same forms of myopathy, with rhabdomyolysis being a more severe form of myopathy. Gabapentin is frequently used in patients with spinal cord injury for neuropathic pain. We report a case of probable gabapentin-induced myositis in a patient with spinal cord injury who was on an increasing dose of gabapentin.<\/jats:p>\n                  <jats:p>This paraplegic patient was receiving an increasing dose of gabapentin for neuropathic pain in the lower limbs. Gabapentin-induced myositis was diagnosed by a combination of new-onset generalized body pain with tenderness, an increase in creatine kinase, elevated myoglobin levels, and a score of 6 on the Naranjo adverse drug reaction probability scale. Withdrawal of the gabapentin resolved the symptoms completely. Blood parameters became normal within two weeks.<\/jats:p>\n                  <jats:p>We suggest that myopathy, in the form of myositis, should be recognized as a potential side effect of gabapentin in the literature.<\/jats:p>","DOI":"10.5339\/qmj.2020.30","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:30:56Z","timestamp":1605141056000},"source":"Crossref","is-referenced-by-count":6,"title":["Gabapentin-induced myositis in a patient with spinal cord injury \u2013 a case report"],"prefix":"10.5339","volume":"2020","author":[{"given":"Sabyasachi","family":"Ghosh","sequence":"first","affiliation":[{"name":"Physical Medicine and Rehabilitation Department, Qatar Rehabilitation Institute, Hamad Medical Corporation, Doha, Qatar E-mail: sghosh@hamad.qa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarafdheen","family":"Villan","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Department, Qatar Rehabilitation Institute, Hamad Medical Corporation, Doha, Qatar E-mail: sghosh@hamad.qa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa","family":"Al Yazeedi","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Department, Qatar Rehabilitation Institute, Hamad Medical Corporation, Doha, Qatar E-mail: sghosh@hamad.qa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3277","reference":[{"key":"CIT0001","unstructured":"Kaya, YE. An evaluation of gabapentin and pregabalin usage in the treatment of neuropathic pain related to spinal cord injury. Ann Med Res. 2019;26(3):521\u20138\n."},{"key":"CIT0002","unstructured":"Coupal TM, Chang DR, Pennycooke K, Ouellette HA, Munk PL. Radiologic findings in gabapentin-induced myositis. J Radiol Case Rep. 2017;11(4):30\u20137\n."},{"key":"CIT0003","unstructured":"Qiu X, Tackett E, Zeid K. A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clin Case Rep. 2019 Jul 11;7(8):1596\u20139\n."},{"key":"CIT0004","unstructured":"American Spinal Injury Association.\u00a0International Standards for Neurological Classifications of Spinal Cord Injury. revised ed. Chicago, Ill: American Spinal Injury Association. 2000;1\u201323\n."},{"key":"CIT0005","unstructured":"Wright J. Functional independence measure. In: Kreutzer J.S., DeLuca J., Caplan B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, New York, NY 2011\n."},{"key":"CIT0006","unstructured":"Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. J Gen Intern Med. 2007;22(10):1453\u20138\n."},{"key":"CIT0007","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345\n."},{"key":"CIT0008","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [Internet]. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4].\u00a0Available from: \nhttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/\n\n."},{"key":"CIT0009","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33(9):2337\u201341\n."},{"key":"CIT0010","unstructured":"Keltz E, Khan FY, Mann G. Rhabdomyolysis: the role of diagnostic and prognostic factors. Muscles Ligaments Tendons J. 2013;3(4):303\u201312\n."},{"key":"CIT0011","unstructured":"Tuccori M, Lombardo G, Lapi L, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. Ann Pharmacother. 2007;41(7):1301\u20135\n."},{"key":"CIT0012","unstructured":"\u00a0Jones JD, Kirsch HL, Wortmann RL, Pillinger MH. The causes of drug-induced muscle toxicity.\u00a0Curr Opin Rheumatol. 2014;26(6):697\u2013703\n."},{"key":"CIT0013","unstructured":"\u00a0Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46(3):409\u201327\n."},{"key":"CIT0014","unstructured":"Joint Formulary Committee.\u00a0BNF 70 (British National Formulary September 2015-March 2016).\u00a0London: BMJ Publishing and the Royal Pharmaceutical Society of Great Britain; 2016\n."},{"key":"CIT0001","unstructured":"Kaya, YE. An evaluation of gabapentin and pregabalin usage in the treatment of neuropathic pain related to spinal cord injury. Ann Med Res. 2019;26(3):521\u20138\n."},{"key":"CIT0002","unstructured":"Coupal TM, Chang DR, Pennycooke K, Ouellette HA, Munk PL. Radiologic findings in gabapentin-induced myositis. J Radiol Case Rep. 2017;11(4):30\u20137\n."},{"key":"CIT0003","unstructured":"Qiu X, Tackett E, Zeid K. A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clin Case Rep. 2019 Jul 11;7(8):1596\u20139\n."},{"key":"CIT0004","unstructured":"American Spinal Injury Association.\u00a0International Standards for Neurological Classifications of Spinal Cord Injury. revised ed. Chicago, Ill: American Spinal Injury Association. 2000;1\u201323\n."},{"key":"CIT0005","unstructured":"Wright J. Functional independence measure. In: Kreutzer J.S., DeLuca J., Caplan B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, New York, NY 2011\n."},{"key":"CIT0006","unstructured":"Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. J Gen Intern Med. 2007;22(10):1453\u20138\n."},{"key":"CIT0007","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345\n."},{"key":"CIT0008","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [Internet]. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4].\u00a0Available from: \nhttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/\n\n."},{"key":"CIT0009","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33(9):2337\u201341\n."},{"key":"CIT0010","unstructured":"Keltz E, Khan FY, Mann G. Rhabdomyolysis: the role of diagnostic and prognostic factors. Muscles Ligaments Tendons J. 2013;3(4):303\u201312\n."},{"key":"CIT0011","unstructured":"Tuccori M, Lombardo G, Lapi L, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. Ann Pharmacother. 2007;41(7):1301\u20135\n."},{"key":"CIT0012","unstructured":"\u00a0Jones JD, Kirsch HL, Wortmann RL, Pillinger MH. The causes of drug-induced muscle toxicity.\u00a0Curr Opin Rheumatol. 2014;26(6):697\u2013703\n."},{"key":"CIT0013","unstructured":"\u00a0Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46(3):409\u201327\n."},{"key":"CIT0014","unstructured":"Joint Formulary Committee.\u00a0BNF 70 (British National Formulary September 2015-March 2016).\u00a0London: BMJ Publishing and the Royal Pharmaceutical Society of Great Britain; 2016\n."}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2020\/2\/article-30.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2020\/2\/article-30.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2020\/2\/article-30.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:20:44Z","timestamp":1777310444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2020\/2\/article-30.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":28,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2020.30","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}